Sat.May 09, 2020

article thumbnail

[OurCrowd CEO Jon Medved in The Jerusalem Post] Expect a ‘renaissance’ in medical innovation, says OurCrowd chief

OurCrowd

Jonathan Medved, CEO of the Jerusalem-based global investment platform OurCrowd, told The Media Line that the outbreak had shifted the focus of many investors in a way that could have far-reaching implications for medical innovation. Read more here. The post [OurCrowd CEO Jon Medved in The Jerusalem Post] Expect a ‘renaissance’ in medical innovation, says OurCrowd chief appeared first on OurCrowd.

article thumbnail

[MigVax in The Jerusalem Post] Expect a ‘renaissance’ in medical innovation, says OurCrowd chief

OurCrowd

According to Medved, MigVax’s new COVID-19 vaccine will be adapted from this research. Importantly, it will be administered orally, making it particularly helpful for rapid use and distribution in developing countries. Read more here. The post [MigVax in The Jerusalem Post] Expect a ‘renaissance’ in medical innovation, says OurCrowd chief appeared first on OurCrowd.